| The molecular taxonomy of primary prostate cancer A Abeshouse, J Ahn, R Akbani, A Ally, S Amin, CD Andry, M Annala, ... Cell 163 (4), 1011-1025, 2015 | 2647 | 2015 |
| Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer CE Barbieri, SC Baca, MS Lawrence, F Demichelis, M Blattner, ... Nature genetics 44 (6), 685-689, 2012 | 1736 | 2012 |
| Punctuated evolution of prostate cancer genomes SC Baca, D Prandi, MS Lawrence, JM Mosquera, A Romanel, Y Drier, ... Cell 153 (3), 666-677, 2013 | 1423 | 2013 |
| The long tail of oncogenic drivers in prostate cancer J Armenia, SAM Wankowicz, D Liu, J Gao, R Kundra, E Reznik, ... Nature genetics 50 (5), 645-651, 2018 | 746 | 2018 |
| Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis CE Barbieri, LJ Tang, KA Brown, JA Pietenpol Cancer research 66 (15), 7589-7597, 2006 | 309 | 2006 |
| The mutational landscape of prostate cancer CE Barbieri, CH Bangma, A Bjartell, JWF Catto, Z Culig, H Grönberg, ... European urology 64 (4), 567-576, 2013 | 292 | 2013 |
| Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4 X Dai, W Gan, X Li, S Wang, W Zhang, L Huang, S Liu, Q Zhong, J Guo, ... Nature medicine 23 (9), 1063-1071, 2017 | 291 | 2017 |
| Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover C Geng, B He, L Xu, CE Barbieri, VK Eedunuri, SA Chew, M Zimmermann, ... Proceedings of the National Academy of Sciences 110 (17), 6997-7002, 2013 | 257 | 2013 |
| DNA repair in prostate cancer: biology and clinical implications J Mateo, G Boysen, CE Barbieri, HE Bryant, E Castro, PS Nelson, ... European urology 71 (3), 417-425, 2017 | 226 | 2017 |
| SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K/mTOR and AR signaling M Blattner, D Liu, BD Robinson, D Huang, A Poliakov, D Gao, S Nataraj, ... Cancer cell 31 (3), 436-451, 2017 | 209 | 2017 |
| FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes EJ Adams, WR Karthaus, E Hoover, D Liu, A Gruet, Z Zhang, H Cho, ... Nature 571 (7765), 408-412, 2019 | 207 | 2019 |
| SPOP mutation leads to genomic instability in prostate cancer G Boysen, CE Barbieri, D Prandi, M Blattner, SS Chae, A Dahija, ... Elife 4, e09207, 2015 | 197 | 2015 |
| p63 and epithelial biology CE Barbieri, JA Pietenpol Experimental cell research 312 (6), 695-706, 2006 | 181 | 2006 |
| SPOP mutations in prostate cancer across demographically diverse patient cohorts M Blattner, DJ Lee, C O'Reilly, K Park, TY MacDonald, F Khani, KR Turner, ... Neoplasia 16 (1), 14-W10, 2014 | 174 | 2014 |
| Evidence for molecular differences in prostate cancer between African American and Caucasian men F Khani, JM Mosquera, K Park, M Blattner, C O'Reilly, TY MacDonald, ... Clinical Cancer Research 20 (18), 4925-4934, 2014 | 172 | 2014 |
| The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study DM Golombos, A Ayangbesan, P O'Malley, P Lewicki, LM Barlow, ... Urology 111, 122-128, 2018 | 170 | 2018 |
| N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer A Berger, NJ Brady, R Bareja, B Robinson, V Conteduca, MA Augello, ... The Journal of clinical investigation 129 (9), 3924-3940, 2019 | 150 | 2019 |
| Association of procedure volume with radical cystectomy outcomes in a nationwide database CE Barbieri, B Lee, MS Cookson, J Bingham, PE Clark, JA Smith, ... The Journal of urology 178 (4), 1418-1422, 2007 | 144 | 2007 |
| SPOP-mutated/CHD1-deleted lethal prostate cancer and abiraterone sensitivity G Boysen, DN Rodrigues, P Rescigno, G Seed, D Dolling, R Riisnaes, ... Clinical cancer research 24 (22), 5585-5593, 2018 | 143 | 2018 |
| TMPRSS2:ERG Gene Fusion Predicts Subsequent Detection of Prostate Cancer in Patients With High-Grade Prostatic Intraepithelial Neoplasia K Park, JT Dalton, R Narayanan, CE Barbieri, ML Hancock, DG Bostwick, ... Journal of clinical oncology 32 (3), 206-211, 2014 | 127 | 2014 |
Mark A RubinProfessor & Director Department for BioMedical Research, University of Bern在 dbmr.unibe.ch 的电子邮件经过验证
